ArticleFrontiers in pharmacology2025
Predicting tigecycline-related adverse events in infected patients: a machine learning approach with clinical interpretability.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tigecycline (TGC), while effective against multidrug-resistant infections, is limited by hepatotoxicity and coagulation disorders, yet lacks robust predictive tools. Methods: We developed an online dynamic nomogram to assess these adverse events using retrospective data from 2,553 TGC-treated patients (2020-2025). Seventy-seven clinical features were analyzed using Boruta and the Least Absolute Shrinkage and Selection Operator (LASSO) for feature selection. Seven machine learning (ML) models were evaluated via ten-fold cross-validation, as well as Receiver Operating Characteristic (ROC) curve and calibration curves, with SHapley Additive exPlanations (SHAP) analysis for interpretability and an online dynamic nomogram for clinical translation. Results: Logistic regression (LR) outperformed other algorithms, achieving Area Under the ROC Curve (AUC) values of 0.800 (95% CI: 0.727-0.874) for hepatotoxicity and 0.755 (95% CI: 0.665-0.845) for coagulation dysfunction. Independent risk factors for liver injury included prolonged treatment duration, high dosage, ICU admission, hepatitis B virus (HBV) infection, and elevated baseline levels of lactate dehydrogenase (LDH) and gamma-glutamyl transferase (GGT). Risk factors for coagulation dysfunction included extended treatment duration, ICU admission, elevated baseline creatinine (Cr), sepsis, and septic shock. Notably, co-administration of meloxicillin and higher baseline red blood cell (RBC) levels appeared to be protective. Conclusion: This study constructed an online dynamic nomogram with good discrimination and calibration, which can help to identify high-risk patients and assist clinicians in early risk stratification and individualized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.